Open AccessAssociation between specific antiarrhythmic drug prescription in the post-procedural blanking period and recurrent atrial arrhythmias after catheter ablation for atrial fibrillation
Author(s) -
Chaitanya Malladi,
Douglas Darden,
Omar M. Aldaas,
Praneet Mylavarapu,
Michael Eskander,
Florentino Lupercio,
Frederick T. Han,
Kurt S. Hoffmayer,
Farshad Raissi,
Gordon Ho,
David E. Krummen,
Gregory K. Feld,
Jonathan C. Hsu
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0253266
Subject(s) - dronedarone , amiodarone , medicine , flecainide , atrial fibrillation , cardiology , atrial flutter , catheter ablation , propafenone , discontinuation , atrial tachycardia , dofetilide , antiarrhythmic agent , ablation , sotalol , anesthesia , heart disease
Purpose To evaluate if specific AADs prescribed in the blanking period (BP) after catheter ablation of atrial fibrillation (AF) may be associated with reduced risk of early recurrence (ER) and/or late recurrence (LR) of atrial arrhythmias. Methods A total of 478 patients undergoing first-time ablation at a single institution were included. Outcomes were: ER, LR, discontinuation of AAD less than 90 days post-ablation, and second ablation. ER was defined as AF, atrial flutter (AFL), or atrial tachycardia (AT) > 30 seconds within BP. LR was defined as AF/AFL/AT > 30 seconds after BP. Results Of 478 patients, 14.9% were prescribed no AAD, 26.4% propafenone/flecainide, 34.5% sotalol/dofetilide, 10.7% dronedarone, and 13.6% amiodarone. Patients prescribed amiodarone were more likely to have persistent AF, hypertension, diabetes, and other comorbidities. In unadjusted analyses, there were no differences between groups in relation to ER (log rank P = 0.171), discontinuation of AAD before ninety days post-ablation (log rank P = 0.235), or freedom from second ablation (log rank P = 0.147). After multivariable adjustment, patients prescribed amiodarone or dronedarone were more likely to experience LR than those prescribed no AAD [Adjusted Hazard Ratio (AHR) 1.83, 95% CI 1.10–3.04, p = 0.02; AHR 1.79, 95% CI 1.05–3.05, p = 0.03, respectively]. Conclusion Following first-time catheter ablation, there were no differences between specific AAD prescription and risk of ER, while those prescribed amiodarone or dronedarone in the BP were more likely to experience LR than those prescribed no AAD, which may represent an association due to confounding by indication.